Literature DB >> 15548407

Management of breech presentation in areas with high prevalence of HIV infection.

W R Holmes1, G J Hofmeyr.   

Abstract

OBJECTIVE: To provide recommendations for the management of breech presentation in areas of high prevalence of human immunodeficiency virus (HIV) infection.
METHOD: Review of relevant literature.
RESULTS: Studies show that elective cesarean section (CS) is safer than vaginal delivery for breech presentation, external cephalic version (ECV) at term increases the chance of vaginal cephalic delivery. Although there are no studies of the risk of mother-to-child transmission of HIV from ECV, indirect evidence suggests that any increased risk is likely to be very small. RECOMMENDATIONS: Where CS is available and safe, HIV-positive women, or women who might be at risk of HIV, with a fetus at term with breech presentation, should be offered elective CS to reduce the risks of both vaginal breech delivery and mother-to-child HIV infection. HIV-negative women can be offered ECV at term to try to avoid CS. Where women do not have access to a safe CS, or prefer vaginal delivery, the benefit for both mother and child of attempting ECV at term is likely to outweigh the theoretical, very small, risk of facilitating HIV transmission.

Entities:  

Mesh:

Year:  2004        PMID: 15548407     DOI: 10.1016/j.ijgo.2004.08.009

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

Review 1.  Fundal pressure during the second stage of labour.

Authors:  G Justus Hofmeyr; Joshua P Vogel; Anna Cuthbert; Mandisa Singata
Journal:  Cochrane Database Syst Rev       Date:  2017-03-07

Review 2.  External cephalic version for breech presentation at term.

Authors:  G Justus Hofmeyr; Regina Kulier; Helen M West
Journal:  Cochrane Database Syst Rev       Date:  2015-04-01

3.  HIV in pregnancy - An update.

Authors:  Victor N Chilaka; Justin C Konje
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2020-11-12       Impact factor: 2.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.